Debanjana Chatterjee
Stock Analyst at Jones Trading
(3.71)
# 721
Out of 5,154 analysts
15
Total ratings
84.62%
Success rate
20.7%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Debanjana Chatterjee
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NTLA Intellia Therapeutics | Upgrades: Buy | $29 | $13.44 | +115.77% | 3 | Mar 4, 2026 | |
| ARMP Armata Pharmaceuticals | Initiates: Buy | $15 | $10.60 | +41.51% | 1 | Jan 5, 2026 | |
| SYRE Spyre Therapeutics | Upgrades: Buy | $64 | $40.15 | +59.40% | 2 | Dec 1, 2025 | |
| SION Sionna Therapeutics | Initiates: Buy | $46 | $35.93 | +28.03% | 1 | Sep 8, 2025 | |
| TBPH Theravance Biopharma | Initiates: Buy | $24 | $13.57 | +76.86% | 1 | Jun 17, 2025 | |
| SGMT Sagimet Biosciences | Maintains: Buy | $15 → $27 | $5.41 | +399.08% | 2 | Jun 6, 2025 | |
| TVRD Tvardi Therapeutics | Initiates: Buy | $39 | $3.93 | +892.37% | 1 | Apr 28, 2025 | |
| KALV KalVista Pharmaceuticals | Maintains: Buy | $30 | $16.23 | +84.84% | 2 | Mar 26, 2025 | |
| CTNM Contineum Therapeutics | Initiates: Buy | $23 | $13.88 | +65.71% | 1 | Mar 13, 2025 | |
| PHVS Pharvaris | Initiates: Buy | $46 | $25.91 | +77.54% | 1 | Sep 19, 2024 |
Intellia Therapeutics
Mar 4, 2026
Upgrades: Buy
Price Target: $29
Current: $13.44
Upside: +115.77%
Armata Pharmaceuticals
Jan 5, 2026
Initiates: Buy
Price Target: $15
Current: $10.60
Upside: +41.51%
Spyre Therapeutics
Dec 1, 2025
Upgrades: Buy
Price Target: $64
Current: $40.15
Upside: +59.40%
Sionna Therapeutics
Sep 8, 2025
Initiates: Buy
Price Target: $46
Current: $35.93
Upside: +28.03%
Theravance Biopharma
Jun 17, 2025
Initiates: Buy
Price Target: $24
Current: $13.57
Upside: +76.86%
Sagimet Biosciences
Jun 6, 2025
Maintains: Buy
Price Target: $15 → $27
Current: $5.41
Upside: +399.08%
Tvardi Therapeutics
Apr 28, 2025
Initiates: Buy
Price Target: $39
Current: $3.93
Upside: +892.37%
KalVista Pharmaceuticals
Mar 26, 2025
Maintains: Buy
Price Target: $30
Current: $16.23
Upside: +84.84%
Contineum Therapeutics
Mar 13, 2025
Initiates: Buy
Price Target: $23
Current: $13.88
Upside: +65.71%
Pharvaris
Sep 19, 2024
Initiates: Buy
Price Target: $46
Current: $25.91
Upside: +77.54%